PRME Prime Medicine
- 5.610
- -0.110-1.92%
- 5.610
- 0.0000.00%
Prime Medicine News
Buy Rating Affirmed for Prime Medicine, Inc. on Robust Preclinical Data and Prime Editing Technology Prospects
Jefferies Investment Bank: Assuming the Prime Medicine (PRME.US) rating, adjusted from buy to buy rating, the target price was adjusted from $23.00 to $15.00.
Prime Medicine Analyst Ratings
Jefferies Issues a Buy Rating on Prime Medicine, Inc. (PRME)
Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlook
Wedbush: Reiterates Prime Medicine's (PRME.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.
Prime Medicine Analyst Ratings
Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price Target
Buy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic Progress
Prime Medicine (PRME.US) was first covered by Chardan Capital, giving it a buy rating, with a target price of $17.00.
Prime Medicine Analyst Ratings
Chardan Capital Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $17
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
Prime Medicine (PRME.US) was first covered by TD Cowen, giving it a buy rating.
Prime Medicine Analyst Ratings
Prime Medicine Analyst Ratings
Wedbush Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $12
Analysts' Top Healthcare Picks: Prime Medicine, Inc. (PRME), Alcidion Group Limited (AU:ALC)
Buy Rating Justified: Prime Medicine's Promising Clinical Prospects and Innovative Gene Editing Technology Poised for Growth
Prime Medicine Analyst Ratings
Analysis
Price Target
No Data
